Ruaje këtë postim Ruaje këtë postim

Merrni njoftime per postimet e reja

Search This Blog

Showing posts with label Calcium channel blockers. Show all posts
Showing posts with label Calcium channel blockers. Show all posts

What is the role of calcium channel blockers in the treatment of hypertension ?

What is the role of calcium channel blockers in the treatment of hypertension ?
 

• In the SYST-EUR study nitrendipine showed a reduction in the risk of stroke
inisolated systolic hypertension when compared to diuretics (Lancet 1997; 350: 757-64).
 

• In the Swedish Trial in Old Patients with Hypertension-2 (STOP-2) study, there was some evidence that the risks of myocardial infarction and of heart failure were greater with calcium antagonist based therapy than with ACE-inhibitor based therapy, but there were no clear differences between either of these regimens and a third based on diuretics and beta-blockers (Lancet 1999; 354: 1751-6). In this study 34-39% of patients withdrew from the three treatment regimens.
 

• The International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment
(INSIGHT) trial compared long-acting nifedipine with a diuretic (hydrochlorothiazide and amiloride combination) and found that the calcium channel antagonist was as effective as diuretics in preventing overall cardiovascular or cerebrovascular complications (Lancet 2000; 356: 366-72). There was a marginally significant excess of heart failure with nifedipine-based treatment. Fatal myocardial infarctions were more common in the nifedipine group. There was an 8% excess withdrawal of drug in the nifedipine group because of peripheral oedema whereas serious adverse events were more frequent in the diuretic group.
 

• In the Nordic Diltiazem Study (NORDIL) from Sweden diltiazem was compared with diuretics,
beta-blockers or both (Lancet 2000; 356: 359-65). This study found that diltiazem was as effective as treatment based on diuretics, beta-blockers or both in preventing the primary end point of all stroke, myocardial infarction and other cardiovascular deaths. There was a marginally significant lower risk of stroke in the diltiazem group despite a lesser reduction in blood pressure. In this study, 23% of the patients withdrew from the diltiazem-based group and 7% withdrew from diuretic-based and beta-blocker based therapy.
What is the role of calcium channel blockers in the treatment of hypertension ?
 

• In the SYST-EUR study nitrendipine showed a reduction in the risk of stroke
inisolated systolic hypertension when compared to diuretics (Lancet 1997; 350: 757-64).
 

• In the Swedish Trial in Old Patients with Hypertension-2 (STOP-2) study, there was some evidence that the risks of myocardial infarction and of heart failure were greater with calcium antagonist based therapy than with ACE-inhibitor based therapy, but there were no clear differences between either of these regimens and a third based on diuretics and beta-blockers (Lancet 1999; 354: 1751-6). In this study 34-39% of patients withdrew from the three treatment regimens.
 

• The International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment
(INSIGHT) trial compared long-acting nifedipine with a diuretic (hydrochlorothiazide and amiloride combination) and found that the calcium channel antagonist was as effective as diuretics in preventing overall cardiovascular or cerebrovascular complications (Lancet 2000; 356: 366-72). There was a marginally significant excess of heart failure with nifedipine-based treatment. Fatal myocardial infarctions were more common in the nifedipine group. There was an 8% excess withdrawal of drug in the nifedipine group because of peripheral oedema whereas serious adverse events were more frequent in the diuretic group.
 

• In the Nordic Diltiazem Study (NORDIL) from Sweden diltiazem was compared with diuretics,
beta-blockers or both (Lancet 2000; 356: 359-65). This study found that diltiazem was as effective as treatment based on diuretics, beta-blockers or both in preventing the primary end point of all stroke, myocardial infarction and other cardiovascular deaths. There was a marginally significant lower risk of stroke in the diltiazem group despite a lesser reduction in blood pressure. In this study, 23% of the patients withdrew from the diltiazem-based group and 7% withdrew from diuretic-based and beta-blocker based therapy.

Namazi

Syzat